Literature DB >> 19046242

How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes?

J B Echouffo-Tcheugui1, L A Sargeant, A T Prevost, K M Williams, R S Barling, R Butler, T Fanshawe, A L Kinmonth, N J Wareham, S J Griffin.   

Abstract

AIMS: To assess the cardiovascular disease (CVD) risk of people with screen-detected Type 2 diabetes and to estimate the risk reduction achievable through early intensive pharmacological intervention.
METHODS: In ADDITION-Cambridge, diabetic patients were identified among people aged 40-69 years through a stepwise screening procedure including a risk score, random and fasting capillary blood glucose, HbA(1c) and oral glucose tolerance test. In those without prior macrovascular disease, 10-year CVD risk was computed using UK Prospective Diabetes Study (UKPDS) and Framingham engines. The absolute risk reduction achievable and its plausible range were predicted using relative risk reductions for individual therapies from published trials and sensitivity analysis.
RESULTS: Of the 867 individuals with undiagnosed diabetes, 19% had pre-existing CVD, 97% were overweight or obese, 86% had hypertension, 75% had dyslipidaemia, 20% had microalbuminuria and 18% were smokers. Of those with hypertension, 35% were not prescribed drugs and 42% were suboptimally treated. Of participants with dyslipidaemia, 68% were not prescribed medications and 22% were poorly controlled. Median 10-year CVD risk was 34.0%[interquartile range (IQR) 26.2-44.6] in men and 21.5% (IQR 15.7-28.7) in women using the UKPDS engine; 38.6% (IQR 27.8-53.0) in men and 24.6% (IQR 17.2-32.9) in women using Framingham equations. In the most conservative scenario (no additive effect of therapies), the absolute risk reduction achievable through multifactorial therapy ranged from 4.9 to 9.5% (UKPDS) and from 5.4 to 10.5% (Framingham). The corresponding ranges of numbers needed to treat were 11-20 and 10-19.
CONCLUSIONS: People with screen-detected diabetes have an adverse cardiovascular risk profile, which is potentially modifiable through application of existing treatment recommendations.

Entities:  

Mesh:

Year:  2008        PMID: 19046242     DOI: 10.1111/j.1464-5491.2008.02600.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

1.  Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study.

Authors:  D R Webb; L J Gray; K Khunti; B Srinivasan; N Taub; S Campbell; J Barnett; A Farooqi; J B Echouffo-Tcheugui; S J Griffin; N J Wareham; M J Davies
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

2.  Intensified glucose lowering in type 2 diabetes: time for a reappraisal.

Authors:  J S Yudkin; B Richter; E A M Gale
Journal:  Diabetologia       Date:  2010-08-05       Impact factor: 10.122

3.  Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort.

Authors:  R K Simmons; M Rahman; R W Jakes; M F Yuyun; A R Niggebrugge; S H Hennings; D R R Williams; N J Wareham; S J Griffin
Journal:  Diabetologia       Date:  2010-10-27       Impact factor: 10.122

4.  Cardiovascular disease in type 2 diabetes: Attributable risk due to modifiable risk factors.

Authors:  John Zeber; Michael L Parchman
Journal:  Can Fam Physician       Date:  2010-08       Impact factor: 3.275

5.  How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort.

Authors:  M Rahman; R K Simmons; S H Hennings; N J Wareham; S J Griffin
Journal:  Diabetologia       Date:  2012-01-12       Impact factor: 10.122

6.  Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.

Authors:  D R Webb; K Khunti; B Srinivasan; L J Gray; N Taub; S Campbell; J Barnett; J Henson; S Hiles; A Farooqi; S J Griffin; N J Wareham; M J Davies
Journal:  Trials       Date:  2010-02-19       Impact factor: 2.279

7.  Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study.

Authors:  Parinya Chamnan; Rebecca K Simmons; Kay-Tee Khaw; Nicholas J Wareham; Simon J Griffin
Journal:  BMJ       Date:  2010-04-23

8.  Racial disparities in lipid control in patients with diabetes.

Authors:  Darcy Saffar; Keoki Williams; Jennifer Elston Lafata; George Divine; Manel Pladevall
Journal:  Am J Manag Care       Date:  2012-06       Impact factor: 2.229

9.  Socio-demographic and behavioural correlates of physical activity perception in individuals with recently diagnosed diabetes: results from a cross-sectional study.

Authors:  Gráinne H Long; Søren Brage; Nicholas J Wareham; Esther M F van Sluijs; Stephen Sutton; Simon J Griffin; Rebecca K Simmons
Journal:  BMC Public Health       Date:  2013-07-24       Impact factor: 3.295

10.  Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): trial protocol.

Authors:  Eleanor Mann; A Toby Prevost; Simon Griffin; Ian Kellar; Stephen Sutton; Michael Parker; Simon Sanderson; Ann Louise Kinmonth; Theresa M Marteau
Journal:  BMC Public Health       Date:  2009-02-20       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.